New York/Copenhagen (dpa -AfX) – In the United States, there were new potentially potentially market -changing news in the field of weight loss medication on Tuesday. What one joy is sorry for the other: While the titles of Eli Lilly on the New York stock exchange due to a pill with a pill attracted almost 4 percent, those of the European competitor Novo Nordisk lost 4.5 percent.
The Lilly titles continued to work with the climb a price slide, which had been given in a first study with the medication with the medication of Orforlipron at the beginning of August. Now the US pharmaceutical company came closer to an approval of the pill. Administration is in competition with the usual medication with syringes, with which Novo Nordisk has had great success in recent years. The shares of the Danes have now interrupted their latest recovery to the highest level since the end of July.
The matter of course is a second decisive study that Lilly wants to show the health authorities that the medication for patients with obesity is safe and effective. Investors are now increasingly worried that the pill could increase competitive pressure on established products. These had temporarily made the Danish pharmaceutical company Novo Nordisk the most valuable European stock exchange company. In this ranking, however, the group has slipped again.
Semolation pills are considered keys to reach more patients on a market that is to grow to $ 95 billion by 2030. So far, researching pills has been a major challenge. Analyst Chris Schott from the US bank JPmorgan emphasized in a first comment that the weight loss from Orforlipron in the current study was comparable to injectable products when the study was highest. He sees the basis for perhaps accelerated approval in mid -2026. Against this background, Eli Lilly remains a “top idea” ./ Tih/la/He
By the way: Eli Lilly and other US shares are even tradable at Finance.net Zero until 11 p.m. (without order fees, plus spreads). Open Depot now for free And secure new customer bonus!
Selected leverage products on Eli Lilly
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Eli Lilly
The lever must be between 2 and 20
Advertising